On September 8, Bausch Health Companies Inc. (NYSE:BHC) and Belgian skincare innovator YUN announced they are extending their microbiome-focused dermatology partnership into Mexico and five additional markets spanning Central and Eastern Europe and Central Asia. The move builds on a 2025 launch in Poland and lands just weeks after the company raised its full-year guidance on the back of a strong second quarter. Together, the two announcements paint a picture of a company using fresh cash flow to chase growth well beyond its home market.
A Global Skincare Land Grab
The YUN expansion is not a small step. Bausch Health has already rolled out YUN’s acne- and eczema-focused probiotic skincare lines in the Czech Republic, Slovakia, Ukraine, and Bulgaria, introduced the products in Mexico, and expects to add Kazakhstan in October 2026. That is six new markets layered onto the original Poland launch, all built around YUN’s live-probiotic skin technology rather than an in-house formula. This kind of partnership lets Bausch Health add shelf space in new geographies without the years of development a homegrown product would require.
The timing lines up with a business that is generating real momentum to fund it. For the second quarter of 2026, Bausch Health posted consolidated revenue of $2.85 billion, up 13% year over year, while adjusted earnings per diluted share climbed 40% to $1.26. Excluding Bausch + Lomb, the company notched its thirteenth straight quarter of year-over-year growth, with the International segment specifically citing strong execution across Latin America and EMEA, the same regions now absorbing the YUN rollout. The Salix segment added further fuel, growing 21% as Xifaxan sales climbed 26%.
Growth Story Has Soft Spots
The expansion also lands next to a segment that is not pulling its weight. Bausch Health’s Diversified segment, which includes Dermatology, came in flat at $219 million in the second quarter, with softer results in Dermatology, Generics, and Dentistry only offset by strength in Neuroscience. That is an odd backdrop for a company simultaneously betting on dermatology-adjacent skincare abroad. The International segment’s headline 10% growth also shrank to 5% on an organic basis once currency effects were stripped out, and softer results in Canada partly offset the EMEA and Latin America gains that management is highlighting.
There is a bigger structural question sitting underneath all of this too. In the same earnings release, Bausch Health said it remains focused on “evaluating all options for unlocking shareholder value,” specifically naming both its Bausch Health and Bausch + Lomb assets. That kind of language usually signals a company still working through how its pieces fit together. Layer on the fact that two of the new YUN markets, Ukraine and Kazakhstan, carry more operational and geopolitical uncertainty than Western Europe, and the expansion looks more ambitious than risk-free.
Funds Retreat As Multiple Shrinks
Hedge fund ownership of Bausch Health fell from 31 funds to 28 in the most recent quarter, a modest but real pullback. Short interest, meanwhile, sits at just 2.75% of the float, which points to little organized betting against the stock. The forward price-to-earnings ratio comes in at a strikingly low 1.34, as of September 15, a multiple that assumes almost nothing about future growth is priced into the shares. That combination is the puzzle this stock currently presents.
What Happens Next Matters
Bausch Health is making a clear bet that its EMEA and Latin America momentum can absorb a rapid, partnership-driven push into new skincare markets. For that bet to pay off, the International segment’s organic growth needs to hold up once currency swings fade, and the six new YUN markets need to scale past introductory sales. For the skeptics, a flat Diversified segment, a shrinking hedge fund base, and an unresolved conversation about unlocking shareholder value suggest the underlying business is more complicated than the expansion headlines let on.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center